Companies starting to take ownership for mitigating AMR but drug resistance outpacing efforts

The article highlights a key takeaway from the Benchmark – the current lack of antimicrobial research and development (R&D) – which is one of the biggest concerns in the battle against drug resistance.

The availability of existing antibiotics in low- and middle-income countries is woefully inadequate, it notes, especially when it comes to products for young children.

Additionally, the article features a prominent example of a pipeline project highlighted in the report – GSK’s gepotidacin for treatment of urinary tract infections (UTIs) – which was recently approved. This marks the first new oral antibiotic class for uncomplicated UTIs in nearly 30 years.

The article ends by acknowledging that while such examples are promising, the pipeline must start catching up with growing resistance to mitigate AMR. It also notes that given the high cost of bringing new products to market, addressing the rate of innovation requires a unified, collective approach by the industry’s stakeholders.